Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for ‌obesity and diabetes in India after ‌patent expiry of the Ozempic active ingredient in late March, it said on ...

The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift ...

The battle among pharmaceutical heavyweights to dominate India's fast-growing anti-obesity market is set to intensify further, with Lupin announcing its entry into the weight-loss injection space. The ...

Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after the semaglutide patent expires in the country, ...

New Delhi — Chinese and Japanese injection molding machinery makers are planning capacity expansions in India to meet growth in the country's domestic market, particularly with higher-tonnage machines ...

A study claims that high blood pressure can be easily controlled with just two injections a year. (Representational image: www.pexels.com) New Delhi: In the past few years, the number of patients with ...